10-K Filing

TEVOGEN BIO HOLDINGS INC. CIK: 1860871 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001410578-22-000810`
Period End Date	20211231
Filing Date	20220401
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	lgstu-20211231x10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 23 Income Statement 7 Cash Flow Statement 24 Stockholders Equity 10

Balance Sheet 23 line items

Line Item	Tag	Value	Unit	Period
Cash	`CashAndCashEquivalentsAtCarryingValue`	$344.58K	USD	Point-in-time
Prepaid expenses and other assets	`PrepaidExpenseAndOtherAssetsCurrent`	$446.61K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$791.19K	USD	Point-in-time
Preferred stock, par value, (per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses- non current	`PrepaidExpenseNoncurrent`	$145.17K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Cash and marketable securities held in Trust Account	`AssetsHeldInTrustNoncurrent`	$351.92M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Total Assets	`Assets`	$352.85M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$39.38K	USD	Point-in-time
Due to affiliate	`DueToAffiliateCurrent`	$20.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$59.38K	USD	Point-in-time
Derivative warrant liabilities	`SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares`	$420.50K	USD	Point-in-time
Deferred underwriting fee payable	`DeferredOfferingCostsNoncurrent`	$14.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$15.18M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Class A ordinary shares subject to possible redemption, $0.0001 par value, 34,500,000 shares at redemption value of $10.20 per share.	`TemporaryEquityCarryingAmountAttributableToParent`	$351.90M	USD	Point-in-time
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding	`PreferredStockValue`	-	USD	Point-in-time
Accumulated Deficit	`RetainedEarningsAccumulatedDeficit`	$-14.23M	USD	Point-in-time
Total shareholders' deficit	`StockholdersEquity`	$-14.23M	USD	Point-in-time
Total shareholders' deficit	`StockholdersEquity`	-	USD	Point-in-time
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS' DEFICIT	`LiabilitiesAndStockholdersEquity`	$352.85M	USD	Point-in-time

Income Statement 7 line items

Line Item	Tag	Value	Unit	Period
General and administrative	`GeneralAndAdministrativeExpense`	$181.42K	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$181.42K	USD	3 Qtrs
Income on investments held in Trust Account	`InvestmentIncomeInterest`	$15.81K	USD	3 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-137.75K	USD	3 Qtrs
Transaction costs allocated to warrant issuance	`SaleOfStockTransactionCostsAllocatedToWarrants`	$880.00	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$152.68K	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-28.75K	USD	3 Qtrs

Cash Flow Statement 24 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-28.75K	USD	3 Qtrs
Interest income on investments held in Trust Account	`InvestmentIncomeInterest`	$15.81K	USD	3 Qtrs
Change in fair value of warrants	`FairValueAdjustmentOfWarrants`	$-137.75K	USD	3 Qtrs
Transaction costs allocated to warrant issuance	`SaleOfStockTransactionCostsAllocatedToWarrants`	$880.00	USD	3 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$591.78K	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$39.38K	USD	3 Qtrs
Due to affiliate	`IncreaseDecreaseInDueToAffiliatesCurrent`	$20.00K	USD	3 Qtrs
Net cash flows used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-713.83K	USD	3 Qtrs
Cash deposited to Trust Account	`PaymentsForInvestmentOfCashInTrustAccount`	$351.90M	USD	3 Qtrs
Net cash flows paid in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-351.90M	USD	3 Qtrs
Proceeds from initial public offering, net of underwriting fees	`NetProceedsFromInitialPublicOffering`	$339.00M	USD	3 Qtrs
Proceeds from sale of private units	`ProceedsFromIssuanceOfPrivatePlacement`	$14.50M	USD	3 Qtrs
Proceeds from issuance of Class B ordinary shares to Sponsor	`ProceedsFromIssuanceOfCommonStock`	$25.00K	USD	3 Qtrs
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	$566.59K	USD	3 Qtrs
Net cash flows provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$352.96M	USD	3 Qtrs
NET CHANGE IN CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$344.58K	USD	3 Qtrs
CASH, BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$344.58K	USD	Point-in-time
CASH, BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
CASH, END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$344.58K	USD	Point-in-time
CASH, END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	-	USD	Point-in-time
Deferred underwriting commissions payable	`DeferredUnderwritingCommissionPayableChargedToAdditionalPaidInCapital`	$14.70M	USD	3 Qtrs
Remeasurement for redeemable shares to redemption value	`AccretionForRedeemableSharesToRedemptionValue`	$39.98M	USD	3 Qtrs
Initial classification of warrant liability	`InitialClassificationOfWarrantLiability`	$558.25K	USD	3 Qtrs
Initial value of Class A ordinary shares subject to possible redemption	`InitialValueOfClassOrdinarySharesSubjectToPossibleRedemption`	$345.00M	USD	3 Qtrs

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning	`StockholdersEquity`	$-14.23M	USD	Point-in-time
Balance at the beginning	`StockholdersEquity`	-	USD	Point-in-time
Issuance of Ordinary Shares to initial shareholders	`StockIssuedDuringPeriodValueNewIssues`	$25.00K	USD	3 Qtrs
Proceeds from Initial Public Offering Costs allocated to Public Warrants (net of offering costs)	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$11.82M	USD	3 Qtrs
Fair value adjustment upon on sale of private placement warrants	`AdjustmentsToAdditionalPaidInCapitalMarkToMarket`	$-588.25K	USD	3 Qtrs
Sale of Private Units	`UnitsIssuedDuringPeriodValueNewIssues`	$14.50M	USD	3 Qtrs
Remeasurement for Class A Ordinary Share to redemption value	`TemporaryEquityAccretionToRedemptionValueAdjustment`	$39.98M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-28.75K	USD	3 Qtrs
Balance at the end	`StockholdersEquity`	$-14.23M	USD	Point-in-time
Balance at the end	`StockholdersEquity`	-	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.